Cgm Dexcom denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for cgm dexcom are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Your Dexcom CGM as Duplicate Therapy

Humana's duplicate-therapy denial for Dexcom CGM means the plan has determined that a glucose-monitoring benefit is already active under your coverage — most commonly a traditional blood glucose meter or a previously authorized CGM system — and considers the Dexcom CGM redundant. This is a coverage-logic determination, not a clinical one, and it is frequently incorrect or overbroad.

The critical clinical distinction to make in your appeal is that a continuous glucose monitor and a fingerstick blood glucose meter are not therapeutically equivalent. A CGM provides trend data, rate-of-change arrows, and customizable alerts that a BGM cannot replicate. If you already have a different CGM, the appeal must explain why your prescriber considers the Dexcom system specifically necessary for your care rather than the currently authorized device.

## Your Federal Appeal Rights

• Internal appeal: File within the deadline shown on your Humana denial notice — typically 60 to 180 days. Humana must decide within 30 days (standard) or 72 hours (expedited/urgent).
• External review (ACA §2719 / ERISA §503): After a final internal denial, you may request independent external review — generally within approximately four months. The IRO decision is binding on Humana.
• Expedited review: Request it in writing if your situation is medically urgent.

## Documentation to Gather

1. Distinct clinical need letter: A letter from your prescribing physician explaining the specific clinical functions of the Dexcom CGM that are not replicated by the currently active monitoring device or benefit. 2. Diagnosis and current regimen: Chart notes confirming your diabetes diagnosis, type, and current insulin or medication regimen. 3. Monitoring history: Records of your existing monitoring device, its limitations in your specific case, and any documented clinical events (hypoglycemic episodes, glucose excursions) attributable to those limitations. 4. Prior device inadequacy documentation: If a prior CGM was tried, document dates, model, and the specific clinical shortcoming that led your prescriber to recommend the Dexcom. 5. Applicable guideline reference: Your prescriber should reference the relevant professional society guidance (e.g., American Diabetes Association) supporting use of CGM with the clinical features you require.

## Criteria-Mapping Structure

Request Humana's CGM coverage policy and its definition of "duplicate therapy." Identify exactly which currently active benefit Humana claims duplicates the Dexcom. For each element of the duplicate-therapy determination, provide a direct, evidence-based response: what the existing benefit provides, what the Dexcom provides differently, and how those differences are clinically material to your management. Attach your prescriber's letter as the clinical anchor for that mapping.

Duplicate-therapy denials for CGM are regularly reversed on appeal when the prescriber clearly articulates the distinct clinical value of the requested device. Do not delay — appeal deadlines are strictly enforced.